By 2025, it’s estimated that the FDA could approve up to 10 to 20 applications per year for cell and gene therapies. And while these technologies promise more effective treatments for patients, they also introduce challenges in access, patient matching, cost, and more.
In a recent on-demand webinar, The Role of Digital Health in Immuno-oncology Therapy Development and Adoption, we explored how digital health technologies like AI, wearables, and remote patient monitoring can tackle these challenges and accelerate the impact of these revolutionary IO therapies.
I was joined by industry thought leaders Arturo Loaiza-Bonilla, M.D., MS.Ed, FACP, Cancer Treatment Centers of America and John Lo, Senior VP, Worldwide Hematology, Bristol Myers Squibb for a lively 30-minute discussion on the topic.
Watch the webinar today for valuable insights on:
John Lo, Senior VP, Worldwide Hematology, Bristol Myers Squibb, shared
“Many health IT systems, wearables, and biopharma companies run on proprietary software. And that means their data doesn’t usually play well with others. Given these silos, oncologists are often missing the data that would help them get a more holistic patient view. This puts a limiting factor on the value of that data. Having a common underlying infrastructure—something that’s interoperable and integrates across systems—is critical.”